Influence of comorbidities on treatment considerations for first-line biologic prescribing in patients with inflammatory bowel disease in the UK
Sign Up to like & getrecommendations! Published in 2022 at "Frontline Gastroenterology"
DOI: 10.1136/flgastro-2021-101995
Abstract: Background Anti-tumour necrosis factor (anti-TNF) therapies are the most commonly used biologics for inflammatory bowel disease (IBD), but for patients with a comorbidity, newer agents may be a more appropriate treatment choice. Aims To investigate… read more here.
Keywords: disease; line biologic; first line; biologic prescribing ... See more keywords